Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report 2026

Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Overview

• Hypertrophic Cardiomyopathy (HCM) Therapeutics market size has reached to $1.37 billion in 2025 • Expected to grow to $1.62 billion in 2030 at a compound annual growth rate (CAGR) of 3.6% • Growth Driver: Rising Incidence Of Cardiovascular Diseases Fuels Growth In Hypertrophic Cardiomyopathy (HCM) Therapeutics Market • Market Trend: Emergence Of Selective Cardiac Myosin Inhibition To Address Hypercontractility • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hypertrophic Cardiomyopathy (HCM) Therapeutics Market?

Hypertrophic cardiomyopathy (HCM) therapeutics refers to a treatment of a condition in which the heart muscle becomes abnormally thick or hypertrophied. The thickening heart muscle makes the heart ineffective at pumping blood. Hypertrophic cardiomyopathy (HCM) therapeutics aim to reduce symptoms and guard against sudden cardiac death in high-risk patients. The main drug types of hypertrophic cardiomyopathy (HCM) therapeutics are antiarrhythmic agents, anticoagulants, beta-adrenergic blocking agents, calcium channel blockers, and others. Antiarrhythmic agents are medications used to treat abnormal heart rhythms or arrhythmias. The device types involved are defibrillators, pacemakers, and others that are used in hospitals and clinics.

What Is The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Growth Forecast?

The hypertrophic cardiomyopathy (hcm) therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.62 billion in 2030 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to growing adoption of novel myosin inhibitors, expansion of genetic screening programs, increasing use of implantable defibrillators, rising focus on personalized cardiology care, improving long-term disease management outcomes. Major trends in the forecast period include increasing adoption of targeted myosin inhibitors, growing focus on early diagnosis and risk stratification, rising use of implantable cardiac devices for sudden death prevention, expansion of combination drug and device-based therapy approaches, higher emphasis on long-term symptom management and quality of life.

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Segmentation

1) By Drug Type: Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Other Drug Types 2) By Device Type: Defibrillators, Pacemakers, Other Device Types 3) By End User: Hospitals, Clinics Subsegments: 1) By Antiarrhythmic Agents: Class I Agents, Class II Agents, Class III Agents, Class IV Agents 2) By Anticoagulants: Vitamin K Antagonists, Direct Oral Anticoagulants (DOACs), Low Molecular Weight Heparins (LMWH) 3) By Beta Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers 4) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines 5) By Other Drug Types: Myosin Inhibitors, Antimetabolites

What Is The Driver Of The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market?

The increasing incidence of cardiovascular diseases (CVD) is expected to propel the growth of the hypertrophic cardiomyopathy (HCM) therapeutics market. Cardiovascular disease (CVD) is a condition that affects the heart or blood vessels. Cardiovascular diseases include heart irregularities such as atrial fibrillation, ventricular fibrillation, and atrioventricular block that require long-term monitoring. The primary need for therapeutics treatment for hypertrophic cardiomyopathy aims to alleviate symptoms and avoid sudden cardiac death in high-risk patients. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, an increase of 4.0% from 224.4 per 100,000 compared to 2023. Therefore, the increasing incidence of cardiovascular diseases (CVD) drives the hypertrophic cardiomyopathy (HCM) therapeutics industry.

Key Players In The Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market

Major companies operating in the hypertrophic cardiomyopathy (hcm) therapeutics market are Merck & Co. Inc., Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Gilead Sciences Inc., Bayer AG, Correvio Pharma Corp., Advanz Pharma Corp., Lupin Limited, Boston Scientific Corporation, Bristol-Myers Squibb Company, Johnson & Johnson, Medtronic plc, Cardiome Pharma Corp., Cytokinetics Inc., Daiichi Sankyo Company Limited, GlaxoSmithKline plc., HUYA Bioscience International LLC, Ionis Pharmaceuticals Inc., Kowa Company Ltd., Luitpold Pharmaceuticals Inc., Menarini Group, Mitsubishi Tanabe Pharma Corporation, Nippon Shinyaku Co. Ltd., Otsuka Holdings Co. Ltd., Servier Laboratories

Global Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Trends and Insights

Major companies operating in the hypertrophic cardiomyopathy therapeutics market are focusing on small molecule allosteric cardiac myosin inhibitors, such as selective myosin modulation, to gain a competitive advantage. These agents reduce excessive contractile force in the myocardium by limiting actin–myosin cross bridge formation. For instance, in December 2024, Cytokinetics, a U.S.-based biopharmaceutical company, received FDA acceptance of its New Drug Application for aficamten, a next generation myosin inhibitor, which demonstrated significant improvements in peak VO₂, reductions in outflow tract gradients, and favorable safety in the pivotal SEQUOIA HCM Phase III trial. This approach offers a disease modifying alternative to symptom relief therapies but introduces regulatory complexity, as highlighted by the submission of a risk mitigation plan (REMS) with the NDA.

What Are Latest Mergers And Acquisitions In The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market?

In November 2023, Merck Sharp & Dohme, a US-based pharmaceutical company, acquired Caraway Therapeutics, Inc. for an undiscloased amount. With the acquisition, Merck aims to leverage its industry-leading research and development capabilities to advance innovative therapies for genetically defined neurodegenerative and rare diseases, ultimately seeking to develop disease-modifying treatments that can significantly alter disease progression. Caraway Therapeutics is a US-based biopharmaceutical company that develops small-molecule therapeutics for rare and neurodegenerative diseases.

Regional Outlook

North America was the largest region in the hypertrophic cardiomyopathy (HCM) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the hypertrophic cardiomyopathy (HCM) therapeutics market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hypertrophic Cardiomyopathy (HCM) Therapeutics Market?

The hypertrophic cardiomyopathy (HCM) therapeutics market consists of revenues earned by entities by provide progressive disease management, physical therapy (PT), and occupational therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypertrophic cardiomyopathy (HCM) therapeutics market also consists of sales of disopyramide, wearable heart monitoring devices, and cardiac rhythm management (CRM) devices which are used in providing hypertrophic cardiomyopathy (HCM) therapeutics services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Report 2026?

The hypertrophic cardiomyopathy (hcm) therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hypertrophic cardiomyopathy (hcm) therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.